A manufacturer document retrieved from a URL containing 2024-09 is actually revised July 2026. Its renal avoid-use restriction remains separate from newer hepatic dosing instructions.
Before applying: Read the document revision, not the URL folder date. Do not apply the hepatic dose reduction as a renal workaround.
Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.
Choose a source to read (2)
Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.
Official source
Pacritinib - VONJO manufacturer prescribing information
Product / population
Adults with specified myelofibrosis and platelets below 50 x 10^9/L; accelerated-approval indication.
Renal measure
MDRD-associated eGFR; source prints mL/min without indexed suffix.
Renal guidance and important limits
Limits that apply to these rows
The usual regimen is 200 mg twice daily. A lower severe-hepatic dose does not create a severe-renal regimen.
Review hemorrhage, QT/electrolytes, diarrhea, infection and interactions. Strong CYP3A4 inhibitors or inducers are contraindicated. No dialysis replacement dose is inferred.
VONJO - renal restriction
Printed eGFR (mL/min)
Source-specific instruction
<30
Avoid use
30-89
Exposure similar to >=90 in the selected renal PK study; this is not an all-patient dosing authorization
Read the retained text before reformatting
VONJO - renal restriction
Printed eGFR (mL/min)
Source-specific instruction
<30
Avoid use
30-89
Exposure similar to >=90 in the selected renal PK study; this is not an all-patient dosing authorization
The usual regimen is 200 mg twice daily. A lower severe-hepatic dose does not create a severe-renal regimen.
Review hemorrhage, QT/electrolytes, diarrhea, infection and interactions. Strong CYP3A4 inhibitors or inducers are contraindicated. No dialysis replacement dose is inferred.
Source revision: 07/2026 | Retrieved: 2026-09-10. Retrieval date is not the revision date.
All sources, comparison tools and evidence navigation
Source-first renal review
Evidence sources and renal implications
Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.
Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.
Find:
Enter at least two characters. Searches stay on this page and are not saved or sent.
All source summaries, original wording and provenance
Before applying a renal protocol
Check the setting. Compare whole sources.
No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.
Share a reproducible source review
Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.
Select two distinct source versions. The complete stored summaries will appear below.
Source-by-source comparison
These protocols may disagree and may apply to different settings. This view does not reconcile or endorse a patient-specific regimen.
Build a source-review outline for documentation
This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.
Choose one or two sources above or use the source checkboxes below.
Renal-context checklist: population, kidney trend and dialysis
These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.
Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.
These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.
source scope and renal guidance
Before use: Pacritinib (VONJO)
A manufacturer document retrieved from a URL containing 2024-09 is actually revised July 2026. Its renal avoid-use restriction remains separate from newer hepatic dosing instructions.
How to use this: Read the document revision, not the URL folder date. Do not apply the hepatic dose reduction as a renal workaround.
Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.
New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.
Official source
Pacritinib - VONJO manufacturer prescribing information
Adults with specified myelofibrosis and platelets below 50 x 10^9/L; accelerated-approval indication.
Method: MDRD-associated eGFR; source prints mL/min without indexed suffix.
No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.
Compare or copy source versions
All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Sobi / VONJO manufacturer prescribing information · Adults with specified myelofibrosis and platelets below 50 x 10^9/L; accelerated-approval indication.
Renal method: MDRD-associated eGFR; source prints mL/min without indexed suffix. Source date: 07/2026 Retrieved: 2026-09-10
Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.
Before using this finding
Read the document revision, not the URL folder date. Do not apply the hepatic dose reduction as a renal workaround.
Selected source sections stored locally. Not a complete monograph or independent clinical approval.
Renal guidance and important limits
Limits that apply to these rows
The usual regimen is 200 mg twice daily. A lower severe-hepatic dose does not create a severe-renal regimen.
Review hemorrhage, QT/electrolytes, diarrhea, infection and interactions. Strong CYP3A4 inhibitors or inducers are contraindicated. No dialysis replacement dose is inferred.
VONJO - renal restriction
Printed eGFR (mL/min)
Source-specific instruction
<30
Avoid use
30-89
Exposure similar to >=90 in the selected renal PK study; this is not an all-patient dosing authorization
Read the retained text before reformatting
VONJO - renal restriction
Printed eGFR (mL/min)
Source-specific instruction
<30
Avoid use
30-89
Exposure similar to >=90 in the selected renal PK study; this is not an all-patient dosing authorization
The usual regimen is 200 mg twice daily. A lower severe-hepatic dose does not create a severe-renal regimen.
Review hemorrhage, QT/electrolytes, diarrhea, infection and interactions. Strong CYP3A4 inhibitors or inducers are contraindicated. No dialysis replacement dose is inferred.
RDM64-official-pacritinib-vonjo-bb997138e1-C1 · Source locator: Sections 1, 2.1-2.2, 4, 8.7 and 12.3; PDF renal PK page inspected.
Source-specific limits
The usual regimen is 200 mg twice daily. A lower severe-hepatic dose does not create a severe-renal regimen.
Review hemorrhage, QT/electrolytes, diarrhea, infection and interactions. Strong CYP3A4 inhibitors or inducers are contraindicated. No dialysis replacement dose is inferred.
GlobalRPh-hosted RX List · VONJO oral product; severe-renal avoidance.
Renal method: Source eGFR below 30 mL/min; pharmacokinetic analysis used MDRD. Source date: Source revision date not established in selected retrieval. Retrieved: 2026-09-07
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
Avoid VONJO when eGFR is below 30. Pharmacokinetic observations in severe impairment and dialysis do not establish an acceptable reduced regimen in that population. The experimental study dose is not a prescribing recommendation. Reconcile the source's renal method and full product safety instructions rather than treating this as a general JAK-inhibitor class rule.
RDM40-rxlist-pacritinib-vonjo-d16a857fc5-C1 · Source locator: Selected renal dosing, renal impairment, toxicity and pharmacokinetic subsections as identified in the summary.
Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.
This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.